Grandchildren provide inspiration in cancer fight
Every moment is precious because he does not know how much time he has left.
Cancer is the problem and if Tippen does not find enough money for treatment, he will have less time with Lily and his other grandchildren – Millie, 8, Mia, 9, and Henry, 7.
'I'm not sure if it's selfish or whatever, but I really want to do what I can to make sure she remembers me,' Tippen said.
The 65-year-old found out he had rectal cancer in February 2020 after getting a scan because he was concerned about some bleeding.
Another scan later revealed the cancer had spread to his liver and lungs.
Tippen started chemotherapy on the first day of level four Covid-19 lockdown.
Given only months to live, he has beaten the odds and has been living with cancer for more than five years.
Tippen cherishes time with all his grandchildren along with his wife Chris and adult children, Laura and Ben.
Tippen's life expectancy today is unclear, but there is a hope of holding off further tumour growth for a few months with a particular treatment regime.
A small number of patients have responded especially well to the treatment and had tumour growth slowed for even longer.
But the cost is steep – more than $11,000 a month for six months.
Tippen requires the drugs Lonsurf and Vegzelma, neither of which are funded by Pharmac in his case.
Pharmac pharmaceuticals director Geraldine MacGibbon said Vegzelma is funded for some types of inoperable liver cancer which have spread to other parts of the body.
There had been no application to Pharmac for Lonsurf to be funded, she said.
Tippen does not qualify for Vegzelma funding as his cancer originated in his rectum rather than his liver.
His family has launched a Givealittle campaign to help cover treatment costs and possibly fund a short holiday for him and Chris.
Tippen will start the treatment in coming weeks and will need five more monthly rounds.
While he can pay for the first round of treatment with the help of insurance, the rest will need to be paid for through fundraising.
Tippen is no stranger to the radiology field, having spent 18 years in IT at Pacific Radiology.
Receiving treatment in the near-empty St George's Hospital on the first day of lockdown was surreal.
'Of course there's always a focus on patient first, but in my job there was not much patient interaction. So you sort of end up viewing people as numbers and not quite real,' he said.
Tippen was nervous about treatment but was encouraged by the kindness shown towards patients.
'Being on the other side of the fence now, you really get to see what an amazing job the CT techs and MRI techs do handling the patients. There's a lot of care there,' he said.
Before retiring on medical leave in 2022, Tippen helped maintain and monitor the complex computer systems inside MRI and CT scanners.
These days, the most important thing for him is spending as much time as possible with his grandchildren. He is currently on school drop-off duty most days during the week and enjoys taking the grandchildren out on weekend activities.
Like many families in similar situations, Tippen and his wife have considered the possibility of selling their home to help pay for the treatment.
'You have to really weigh all that stuff up. It's very hard to balance up the extra time you get with these drugs with selling the house off. My wife is in perfect health so I don't want to leave her with nothing,' he said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NZ Herald
a day ago
- NZ Herald
Robert F. Kennedy jnr and American Academy of Pediatrics clash over Covid shots for kids
In an X post, Kennedy responded to the AAP's new vaccine recommendations by calling them 'corporate-friendly' and blasting the medical organisation for receiving donations from vaccine manufacturers. He said the organisation should disclose its 'corporate entanglements' and conflicts of interest 'so that Americans may ask whether the AAP's recommendations reflect public health interest, or are, perhaps, just a pay-to-play scheme to promote commercial ambitions of AAP's Big Pharma benefactors'. Susan Kressly, AAP's president, said her group welcomes an opportunity to meet Kennedy to discuss the recommendations. 'This attack on the integrity of paediatricians is unfortunate, but it does not change the facts,' Kressly said in a statement. 'We are transparent about our funders, follow rigorous conflict-of-interest disclosures and maintain safeguards to ensure the integrity and independence of our guidance.' The country is in the midst of a summer uptick in coronavirus cases, and the future of vaccine access is uncertain. The Centres for Disease Control and Prevention (CDC) did not go as far as Kennedy directed and did not remove coronavirus vaccines from the childhood immunisation schedule. Instead, the public health agency softened its recommendation for all children to receive an annual coronavirus shot. It now recommends parents consult a doctor to decide whether to vaccinate their children. The AAP took a similar approach for older children. Its new guide says healthy children ages 2 to 18 can receive a coronavirus vaccine if their parents or guardians want them to have that protection. Few parents do. The CDC estimates that 13% of all eligible children are up to date on coronavirus vaccines, as well as 4.5% of children between the ages of 6 months and 23 months. By issuing a broader coronavirus vaccine recommendation for young children, the AAP is trying to boost uptake and keep the shots free. Between October 2022 and April 2024, a little more than half of children between the ages of 6 months and 23 months admitted to intensive care for Covid had no underlying conditions, a CDC study found. Still, the vast majority of children infected by coronavirus will have mild symptoms, and few will become hospitalised. Health officials say it has become difficult to measure the effectiveness of coronavirus vaccines in young children because the vaccination rates are so low. Limited data shows the 2024-2025 coronavirus vaccines provided extra protection against severe illness in children and adults compared with people who did not receive a vaccine, according to CDC data presented in June. But paediatric infectious-disease specialists have argued that regularly vaccinating children makes sense as a public health strategy because evidence has shown each year that protection in children is similar to that seen in adults. Federal officials have yet to approve or recommend an updated coronavirus vaccine, which usually debuts in late summer. The Food and Drug Administration (FDA) has signalled it would not license upcoming coronavirus vaccines for otherwise healthy children. Kennedy recently fired all members of the CDC's Advisory Committee on Immunisation Practices, a group of experts who decide who should receive FDA-approved or authorised vaccines. Four of the seven members Kennedy appointed as replacements have been publicly critical of the broad use of coronavirus vaccines. For the past three decades, the AAP and the CDC have been mostly aligned in their vaccine recommendations – until now. The AAP's schedule 'differs from recent recommendations of the Advisory Committee on Immunisation Practices (Acip) of the CDC, which was overhauled this year and replaced with individuals who have a history of spreading vaccine misinformation', the organisation said in a statement. Retsef Levi, an Acip member who has denounced the use of mRNA coronavirus vaccines, criticised the AAP's recommendation in an X post, arguing Covid poses 'zero risk' to babies and the shots could damage their hearts. His message was reposted by Robert Malone, another Acip member who has been critical of coronavirus vaccines. Under federal law, insurers must cover the cost of Acip-recommended vaccinations. The AAP and other professional organisations have been holding discussions with insurance companies to continue covering the shots based on guidance from professional associations rather than the federal Government. O'Leary said insurers 'are signalling that they are committed to covering our recommendations'. Ahip (formerly America's Health Insurance Plans), the major insurance lobby, has said its members are committed to continuing to pay for respiratory virus vaccines this season. The new Acip panel did not make any coronavirus recommendations when it met for the first time in late June. It may not even convene a special meeting to discuss the coronavirus vaccines until mid-September, according to industry employees and CDC officials who spoke on the condition of anonymity to share sensitive information. That timing has become more uncertain after the August 8 shooting at the CDC that severely damaged several buildings and traumatised CDC staff. The Acip is scheduled to hold a meeting in October. The AAP's full vaccine guidance, published on Tuesday in the organisation's clinical guidebook for infectious-diseases prevention and treatment, represents formal recommendations for immunisations for infants, children and adolescents against 18 diseases. Its recommendations for flu and respiratory syncytial virus, or RSV, are essentially the same as what federal health officials, including Kennedy, have recommended.
NZ Herald
3 days ago
- NZ Herald
Kiwi family move to Australia to get cystic fibrosis drug Trikafta for daughter
Adalyn Delaney was suffering the effects of CF before she was even born, with health staff discovering during a scan that she had a bowel obstruction. The moment she was born, she had to be rushed away to surgery. Adalyn Delaney, 4, moved to Australia with her family, including 1-year-old Emily Delaney, to access Trikafta. Adalyn had to have two surgeries within her first five weeks of life, and another at the age of 1 to get scar tissue removed. She has been hospitalised multiple times, including for pneumonia, a collapsed lung and another bowel obstruction. She has to go on a nebuliser (a mask-like device that turns medicine into a vapour she can inhale) three times a day when she is healthy, and must take medication when she eats to help her body digest food properly. Before going on Trikafta, she went on antibiotics every time she got a cough. Since getting to Queensland in June, Adalyn was quickly prescribed Trikafta and has been on what she calls her 'special pill' now for several weeks. While it is still early days, the medication appears to be working well so far, with Adalyn experiencing a spike in energy and hunger, and a lack of tummy aches. Delaney said it was 'really heartbreaking' to leave behind their support networks, friends and family, but they had to make the decision for Adalyn's health. 'Children don't want to be strapped to nebulisers, they want to be playing and all that.' Delaney said it was disappointing it was 'taking so long' for the drug to be funded for young children in New Zealand. Adalyn Delaney calls Trikafta her "special pill". 'It's definitely a condition that affects things from birth ... the sooner the better that children can go on it for better long-term outcomes.' The family have thought about whether they would move home once Adalyn turns 6, but Delaney said Australia was funding more medications that may have a better impact on Adalyn. 'We want NZ to keep pace with treatments, not just catch up. We need to be where she'll get the best care.' 'This can change the trajectory of their lives' The chief executive of Cystic Fibrosis New Zealand, Lisa Burns, said New Zealand was 'just so far behind' other countries in providing Trikafta to children. Children were suffering irreversible damage to their bodies before the age of 6, she said. To the best of her knowledge, about 55 children in New Zealand would benefit from the drug being funded for them. She noted Pharmac's Pharmacology and Therapeutics Advisory Committee previously said Trikafta could add 27 years to someone's life. While previous estimates have put the average life expectancy in the 30s, updated figures in Australia, where more medications have been funded for longer, are closer to the mid-50s. Alex and Kayla Delaney moved their two daughters, Adalyn, 4, and Emily, 1, to Australia to access the drug for Adalyn. 'When children are normally learning to walk and explore, these kids aren't. They're going through hours of treatment regimes and having to spend time in hospital, and they don't get to have the same opportunities, and this medication could drastically help to improve that in this age group. It's so important,' she said. 'My message to Pharmac is please recognise the value that is being delivered from the patient population ... we want to see equitable, accessible treatment for our children. 'I just don't understand why we wouldn't do it, this can change the trajectory of their lives.' 'It was literally life-changing' Hanna Meates, 33, went on Trikafta a couple of years ago when Pharmac began funding it for people over 6. 'Everybody should be able to have access to something like that if it's going to literally save their life ... like, they can avoid all the lung damage and all of that stuff that's irreversible,' the Lower Hutt woman said. It was an opportunity for them 'to have a normal life right off the bat'. 'I think something like Trikafta is the most incredible medical breakthrough that we've had for cystic fibrosis.' Meates had never expected to have a long life, and upon starting Trikafta, her emotions were 'quite indescribable'. 'For the first time, I actually had a future to look forward to and a future that I could plan for and know that I was going to have that and be healthy for at least most of it. 'It was amazing but also scary in a way as well, because like, you grow up and you're told that ... you're not probably going to have a long life. So you live your life like that. Hanna Meates, 33, started taking Trikafta for her cystic fibrosis, and said the medication was life-changing. 'I didn't plan for anything. I don't have savings or anything. I didn't care about what was going to happen, so I was just living in the moment, and then suddenly you do have a future and then you have to start thinking about savings and what you're going to do for your future.' Meates said her symptoms were significantly reduced on Trikafta. She still experiences more shortness of breath than the average person and can get quite tired, but aside from that and a persistent cough, she otherwise feels healthy. 'You're one way your whole life and you don't really know what you're missing out on, and then suddenly your life just completely changes.' Before Trikafta, she couldn't exercise or hold down a full-time job, or even go for a light walk without running out of breath. Now she can go to the gym and live life relatively normally, and has a full-time job as an adviser in a government department. 'It was literally life-changing,' she said. Pharmac's director of advice and assessment, Dr David Hughes, said when they funded Trikafta for people over 6 in April 2023, Trikafta only had approval for that age group at the time. 'The company obtained Medsafe approval for Trikafta for children aged 2 to 5 years in March 2025, after supplying clinical trial data for this age group,' he said in a statement. A year ago, a respiratory advisory committee recommended Pharmac fund it with a high priority for people aged 2-6 who met certain criteria. 'Our teams are working hard to finish our assessment of this application, which is well under way. Once our assessment is complete, we will then compare this application against applications for other medicines that people would like us to fund on the Options for Investment list. 'We can't say if or when a decision about funding this medicine will be made. It depends on things like the budget we have available, the success of negotiations with suppliers, and how we've prioritised this medicine against others.' In a statement, Vertex, which makes Trikafta, said more than 40 countries, including those with a similar funding system to New Zealand, were funding the drug. 'Vertex is keen to explore innovative funding solutions with Pharmac so that eligible children ages 2-5 years can have sustainable access to Trikafta as soon as possible.' Melissa Nightingale is a Wellington-based reporter who covers crime, justice and news in the capital. She joined the Herald in 2016 and has worked as a journalist for 10 years.
Techday NZ
3 days ago
- Techday NZ
OneMRI raises AUD $2.5m to expand preventive MRI scan service
Australian startup OneMRI has raised AUD $2.5 million in seed capital to expand its national service offering preventive whole-body MRI scans for early detection of a wide range of health conditions. Funding round The seed round was oversubscribed, with participation from investors including OIF Ventures, TEN13, Antler, Salus Ventures, AfterWork Ventures, Archangel Ventures, Black Sheep Capital, Prtnr, Larsen Ventures, Tribe Global Ventures, as well as several clinicians and radiologists. The funding aims to support OneMRI's growth across Australia to meet increasing consumer interest in proactive health management. OneMRI was founded in October 2024 by Dr. Vu Tran and Andrew Barnes, known for their work at Go1, alongside entrepreneur Gopi Sara. The company markets itself as Australia's first and only national provider of whole-body MRI scans, designed to enable early detection of over 500 potential health conditions including cancers, metabolic disorders, benign growths, autoimmune conditions such as MS, spinal degeneration, and brain aneurysms. Preventive health model The clinical approach at OneMRI is supported by research and development, with scan reviews by radiologists and consultations with doctors to ensure clinical rigour. The scans are intended to complement, not replace, more targeted diagnostic tests. Gopi Sara, OneMRI Co-founder and Chief Executive Officer, described the firm's emphasis on an ethical and patient-focused process. "OneMRI's process is genuinely customer-centric, with a rigorous eligibility and informed consent framework. We have a duty of care to every individual, which is why thoughtful screening is at the core of our approach. Every appointment includes both a pre- and post-scan consultation with qualified clinicians and dedicated care coordinators - ensuring patients fully understand the process, their results and what potential next steps might look like." OneMRI partners with radiology providers such as Scan Medical and Pinnacle Medical Imaging, and collaborates with healthcare professionals and wellness brands including The Banyans, Evergreen Doctors, Melbourne Functional Medicine, and Longev. By partnering with underutilised clinics, the company utilises MRI machines operating below capacity without increasing strain on existing healthcare resources. Sector growth and patient access Dr. Vu Tran, Co-Founder and Head of Medical, OneMRI, highlighted the increasing relevance of preventive health and technology in the sector. "Wellness and preventive health are only going to grow as sectors - and technology will play a critical role in that evolution. Right now, radiology is one of the most underutilised tools in preventive care. The 'health curious' increasingly want autonomy, access, and answers. Individuals should have the agency to take a proactive approach to their health, and whole-body MRI scans are one of the safest ways to do that - offering a multi-system snapshot in a single, radiation-free investigation. Our aim is to increase OneMRI's footprint and accessibility through market growth and product innovation. We've already seen everyday Australians, from schoolteachers to nurses, benefit from our scans, and believe that we have an important part to play as more people take a proactive approach to their long-term health." Early adopters of the service have already identified previously undetected life-threatening conditions. Michelle, 49, a Life Coach from Sydney, commented on her reasons for participating: "I did a preventive MRI not out of fear, but because I believe in being proactive with my health. It gave me peace of mind and reminded me how important it is to listen to our bodies and take care of ourselves before something feels wrong." David Shein, Partner at OIF Ventures, remarked on the investment: "Investing in OneMRI is not only an exceptional opportunity to back a fast-growing sector, but it's also a way for us to support improved and more accessible care for Australians over time. I've been very impressed with what the team has achieved to date, and anticipate strong future growth for the company." Current operations and expansion OneMRI currently provides its services in Brisbane, the Gold Coast, Perth, Sydney, Newcastle, and Melbourne, with further locations expected to be added as expansion continues. The company is also preparing to offer its services across the Asia Pacific region in future international growth plans.
